IDEXX LABORATORIES INC /DE Sales Revenue, Goods, Net (Deprecated 2018-01-31)
IDEXX LABORATORIES INC /DE (IDXX) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $1.18 billion for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-02-16
- IDEXX LABORATORIES INC /DE sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $309.03M, a 14.16% increase year-over-year.
- IDEXX LABORATORIES INC /DE sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $291.03M, a 9.28% increase year-over-year.
- IDEXX LABORATORIES INC /DE sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $304.09M, a 6.74% increase year-over-year.
- IDEXX LABORATORIES INC /DE sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $271.96M, a 9.19% increase year-over-year.
- IDEXX LABORATORIES INC /DE sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $1.18B, a 9.82% increase from fiscal 2016.
- IDEXX LABORATORIES INC /DE sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $1.07B, a 9.85% increase from fiscal 2015.
- IDEXX LABORATORIES INC /DE sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $974.93M, a 8.40% increase from fiscal 2014.
- IDEXX LABORATORIES INC /DE sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $899.41M, a 5.25% increase from fiscal 2013.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $309.03M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $600.06M derived: sum of 2 quarters · filed 2018-02-16 | $904.15M derived: sum of 3 quarters · filed 2018-02-16 | $1.18B 10-K · filed 2018-02-16 |
| 2017-09-30 | $291.03M 10-Q · filed 2017-10-31 | $595.12M derived: sum of 2 quarters · filed 2017-10-31 | $867.09M 10-Q · filed 2017-10-31 | $1.14B derived: sum of 4 quarters · filed 2018-02-16 |
| 2017-06-30 | $304.09M 10-Q · filed 2017-08-01 | $576.06M 10-Q · filed 2017-08-01 | $846.76M derived: sum of 3 quarters · filed 2018-02-16 | $1.11B derived: sum of 4 quarters · filed 2018-02-16 |
| 2017-03-31 | $271.96M 10-Q · filed 2017-04-28 | $542.66M derived: sum of 2 quarters · filed 2018-02-16 | $808.99M derived: sum of 3 quarters · filed 2018-02-16 | $1.09B derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-12-31 | $270.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $537.02M derived: sum of 2 quarters · filed 2018-02-16 | $821.91M derived: sum of 3 quarters · filed 2018-02-16 | $1.07B 10-K · filed 2018-02-16 |
| 2016-09-30 | $266.32M 10-Q · filed 2017-10-31 | $551.21M derived: sum of 2 quarters · filed 2017-10-31 | $800.27M 10-Q · filed 2017-10-31 | $1.05B derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | $284.89M 10-Q · filed 2017-08-01 | $533.95M 10-Q · filed 2017-08-01 | $778.82M derived: sum of 3 quarters · filed 2018-02-16 | $1.03B derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | $249.06M 10-Q · filed 2017-04-28 | $493.94M derived: sum of 2 quarters · filed 2018-02-16 | $740.68M derived: sum of 3 quarters · filed 2018-02-16 | $991.89M derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | $244.87M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $491.62M derived: sum of 2 quarters · filed 2018-02-16 | $742.83M derived: sum of 3 quarters · filed 2018-02-16 | $974.93M 10-K · filed 2018-02-16 |
| 2015-09-30 | $246.75M 10-Q · filed 2016-11-01 | $497.96M derived: sum of 2 quarters · filed 2016-11-01 | $730.06M 10-Q · filed 2016-11-01 | $938.90M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $251.21M 10-Q · filed 2016-08-02 | $483.31M 10-Q · filed 2016-08-02 | $692.15M derived: sum of 3 quarters · filed 2017-02-17 | $925.82M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $232.10M 10-Q · filed 2016-04-29 | $440.94M derived: sum of 2 quarters · filed 2017-02-17 | $674.61M derived: sum of 3 quarters · filed 2017-02-17 | $912.12M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $208.84M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $442.50M derived: sum of 2 quarters · filed 2017-02-17 | $680.02M derived: sum of 3 quarters · filed 2017-02-17 | $899.41M 10-K · filed 2017-02-17 |
| 2014-09-30 | $233.67M 10-Q · filed 2015-10-28 | $471.18M derived: sum of 2 quarters · filed 2015-10-28 | $690.57M 10-Q · filed 2015-10-28 | $915.32M derived: sum of 4 quarters · filed 2016-02-17 |
| 2014-06-30 | $237.51M 10-Q · filed 2015-07-30 | $456.91M 10-Q · filed 2015-07-30 | $681.66M derived: sum of 3 quarters · filed 2016-02-17 | $888.35M derived: sum of 4 quarters · filed 2016-02-17 |
| 2014-03-31 | $219.39M 10-Q · filed 2015-04-28 | $444.14M derived: sum of 2 quarters · filed 2016-02-17 | $650.83M derived: sum of 3 quarters · filed 2016-02-17 | $868.16M derived: sum of 4 quarters · filed 2016-02-17 |
| 2013-12-31 | $224.75M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-17 | $431.44M derived: sum of 2 quarters · filed 2016-02-17 | $648.76M derived: sum of 3 quarters · filed 2016-02-17 | $854.53M 10-K · filed 2016-02-17 |
| 2013-09-30 | $206.69M 10-Q · filed 2014-10-24 | $424.01M derived: sum of 2 quarters · filed 2014-10-24 | $629.78M 10-Q · filed 2014-10-24 | $833.49M derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-06-30 | $217.32M 10-Q · filed 2014-07-25 | $423.09M 10-Q · filed 2014-07-25 | $626.79M derived: sum of 3 quarters · filed 2015-02-17 | $823.69M derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-03-31 | $205.77M 10-Q · filed 2014-04-25 | $409.47M derived: sum of 2 quarters · filed 2015-02-17 | $606.37M derived: sum of 3 quarters · filed 2015-02-17 | $818.59M derived: sum of 4 quarters · filed 2015-02-17 |
| 2012-12-31 | $203.70M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-17 | $400.60M derived: sum of 2 quarters · filed 2015-02-17 | $612.83M derived: sum of 3 quarters · filed 2015-02-17 | $816.99M 10-K · filed 2015-02-17 |
| 2012-09-30 | $196.90M 10-Q · filed 2013-10-22 | $409.12M derived: sum of 2 quarters · filed 2013-10-22 | $613.29M 10-Q · filed 2013-10-22 | $812.72M derived: sum of 4 quarters · filed 2014-02-18 |
| 2012-06-30 | $212.22M 10-Q · filed 2013-07-23 | $416.39M 10-Q · filed 2013-07-23 | $615.82M derived: sum of 3 quarters · filed 2014-02-18 | $807.15M derived: sum of 4 quarters · filed 2014-02-18 |
| 2012-03-31 | $204.17M 10-Q · filed 2013-04-23 | $403.60M derived: sum of 2 quarters · filed 2014-02-18 | $594.93M derived: sum of 3 quarters · filed 2014-02-18 | $798.44M derived: sum of 4 quarters · filed 2014-02-18 |
| 2011-12-31 | $199.43M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-18 | $390.77M derived: sum of 2 quarters · filed 2014-02-18 | $594.27M derived: sum of 3 quarters · filed 2014-02-18 | $782.65M 10-K · filed 2014-02-18 |
| 2011-09-30 | $191.33M 10-Q · filed 2012-10-19 | $394.84M derived: sum of 2 quarters · filed 2012-10-19 | $583.22M 10-Q · filed 2012-10-19 | $771.46M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-06-30 | $203.50M 10-Q · filed 2012-07-20 | $391.89M 10-Q · filed 2012-07-20 | $580.12M derived: sum of 3 quarters · filed 2013-02-19 | $753.42M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-03-31 | $188.38M 10-Q · filed 2012-04-20 | $376.62M derived: sum of 2 quarters · filed 2013-02-19 | $549.92M derived: sum of 3 quarters · filed 2013-02-19 | $729.73M derived: sum of 4 quarters · filed 2013-02-19 |
| 2010-12-31 | $188.24M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-19 | $361.53M derived: sum of 2 quarters · filed 2013-02-19 | $541.35M derived: sum of 3 quarters · filed 2013-02-19 | $718.11M 10-K · filed 2013-02-19 |
| 2010-09-30 | $173.30M 10-Q · filed 2011-10-21 | $353.11M derived: sum of 2 quarters · filed 2011-10-21 | $529.87M 10-Q · filed 2011-10-21 | $713.39M derived: sum of 4 quarters · filed 2012-02-17 |
| 2010-06-30 | $179.81M 10-Q · filed 2011-07-22 | $356.57M 10-Q · filed 2011-07-22 | $540.10M derived: sum of 3 quarters · filed 2012-02-17 | $711.62M derived: sum of 4 quarters · filed 2012-02-17 |
| 2010-03-31 | $176.76M 10-Q · filed 2011-04-21 | $360.28M derived: sum of 2 quarters · filed 2012-02-17 | $531.81M derived: sum of 3 quarters · filed 2012-02-17 | $707.88M derived: sum of 4 quarters · filed 2012-02-17 |
| 2009-12-31 | $183.52M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | $355.05M derived: sum of 2 quarters · filed 2012-02-17 | $531.12M derived: sum of 3 quarters · filed 2012-02-17 | $687.01M 10-K · filed 2012-02-17 |
| 2009-09-30 | $171.53M 10-Q · filed 2010-10-22 | $347.59M derived: sum of 2 quarters · filed 2010-10-22 | $503.49M 10-Q · filed 2010-10-22 | |
| 2009-06-30 | $176.07M 10-Q · filed 2010-07-23 | $331.96M 10-Q · filed 2010-07-23 | ||
| 2008-12-31 | $693.32M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |